300147 深市 香雪制药

          广州市香雪制药股份有限公司

            2020 年度财务决算报告

  广州市香雪制药股份有限公司（以下简称“公司”）2020年度财务报表经大华会计师事务所（特殊普通合伙）审计，会计师的审计意见是标准无保留。现将2020年度财务决算报告如下（均为合并数据）：

  一、主要财务指标

  2020 年，公司实现营业收入 307,209.07 万元，同比增加 10.26%，实现利润
总额 16,613.86 万元，同比增加 41.91%，实现归属于上市公司股东的净利润9,842.10 万元，同比增加 28.63%。主要财务指标如下：

项目                                        2020 年    2019 年    同比增长

基本每股收益（元/股）                              0.15        0.12  25.00%

稀释每股收益（元/股）                              0.15        0.12  25.00%

扣除非经常性损益后的基本每股收益（元/股）            0.22      -0.04 -650.00%

加权平均净资产收益率                              2.77%      2.21%    0.56%

扣除非经常性损益后的加权平均净资产收益率          4.12%      -0.77%    4.89%

每股经营活动产生的现金流量净额（元/股）              0.39        0.13  200.00%

归属于上市公司股东的每股净资产（元/股）              5.47        5.27    3.80%

    二、2020 年度总体经营成果

                                                                      单位：元

      项目            2020 年          2019 年      同比变动    重大变动说明

营业收入          3,072,090,655.97  2,786,199,516.85    10.26%

营业成本          2,079,524,432.40  1,905,396,940.25    9.14%

营业税金及附加      21,663,904.08    20,180,948.78    7.35%

销售费用            339,038,427.13    395,320,628.31  -14.24%

管理费用            244,542,488.20    222,897,543.51    9.71%

研发费用            66,989,910.15    61,268,399.72    9.34%

财务费用            133,337,261.32    152,874,876.93  -12.78%

资产减值损失        -13,448,453.16      -723,584.87  1,758.59%  报告期内口罩产品
                                                              及中药材减值所致

                                                              报告期内，子公司
资产处置收益          -3,569,334.59        -38,713.11  9,119.96%  固定资产处置损失
                                                              增加

                                                              报告期内，公司持
公允价值变动收益      -9,050,579.38      5,206,994.93  -273.82%  有美国ATNX公司
                                                              股票市场价格下跌
                                                              所致


 其他收益            43,960,069.30    35,329,299.62    24.43%

                                                              报告期内处置股权
 投资收益            29,681,302.43    56,435,380.35  -47.41%  投资产生的收益减
                                                              少所致

 其中：对联营企业                                              报告期内，公司持
 和合营企业的投资      -9,228,253.00    -17,417,973.59  -47.02%  有 非 控 股 香 港
 收益                                                          AXIS 公司年度亏
                                                              损所致

                                                              报告期内计提应收
 信用减值损失          -5,318,652.23    -11,899,644.95  -55.30%  款账减值准备减少
                                                              所致

                                                              报告期内营业收入
 营业利润            229,248,585.06    112,569,911.32  103.65%  增长、销售费用下
                                                              降、财务费用下降
                                                              所致

 营业外收入            7,675,721.27      8,303,101.35    -7.56%

 营业外支出          70,785,723.65      3,796,198.71  1,764.65%  报告期内南岳案及
                                                              对外捐赠所致

 所得税费用          24,341,266.01    -9,052,752.38  -368.88%  报告期利润增加所
                                                              得税增加

 归属于母公司所有    98,420,950.34    76,514,355.43    28.63%

 者的净利润

 少数股东损益        43,376,366.33    49,615,210.91  -12.57%  少数股东损益

    三、主营业务收入构成

    1、按产品分类

                                                                      单位：元

  产品        2020 年          2019 年      同比          重大变动说明

                                              变动

 抗病毒口    407,524,484.86  290,936,391.95  40.07%  报告期内抗病毒产品销售增长
 服液

 板蓝根        40,837,474.60    23,023,715.23  77.37%  报告期内板蓝根产品销售增长

 橘红系列    119,885,139.01  257,096,665.00  -53.37%  报告期内橘红产品销售下降

 其他        1,404,934,219.36  1,068,840,720.00  31.44%  报告期防护产品销售增加

 中药材      1,098,909,338.14  1,146,302,024.67  -4.13%

    2、按销售区域分类

                                                                      单位：元

  地区        2020 年          2019 年      同比          重大变动说明

                                              变动

广东省      1,063,395,074.06    790,387,649.10  34.54%  本报告期广东区业务取得进展

 西南区        218,532,396.05    132,042,026.38  65.50%  本报告期西南区业务取得进展

 华中区        984,024,397.73  1,065,781,639.91  -7.67%

 华北、华东    798,427,656.06    784,575,801.46  1.77%

 及东北区

                                            -42.51

 海外            7,711,132.07    13,412,400.00          本报告期境外业务发生减少
                                                %

      四、2020 年末资产负债状况

                                                                        单位：元

    项目          2020 年        2019 年      同比        重大变动说明

                                                  变动

货币资金          605,136,289.00  495,694,143.29  22.08%

交易性金融资产    19,336,861.66    28,544,008.56  -32.26%  公司持有美国 ATNX 公司